MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- IPCA LABORATORIES LIMITED Financial Data
IPCA Labs Fact Sheet (IPLB)
Just Released: The No. 1 Stock to Buy in 2020
Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA LABS Price History
| % ch | % | -0.2 |
| No. of shares | m | 126.20 |
| % ch week | % | -0.8 |
| % ch 1-mth | % | 6.2 |
| % ch 12-mth | % | 56.3 |
| 52 week H/L | Rs | 1,263.9/718.0 |
IPCA LABS Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| IPCA LABS EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 899 | 888 | 643 | 695 | 1,042 | |
| Low | Rs | 591 | 629 | 503 | 400 | 590 | |
| Sales per share (Unadj.) | Rs | 249.2 | 230.3 | 254.5 | 260.2 | 298.6 | |
| Earnings per share (Unadj.) | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
| Diluted earnings per share | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
| Cash flow per share (Unadj.) | Rs | 34.4 | 20.6 | 29.1 | 33.1 | 49.4 | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | 1.00 | 1.00 | 3.00 | |
| Adj. dividends per share | Rs | 1.00 | 0.00 | 1.00 | 1.00 | 3.00 | |
| Dividend yield (eoy) | % | 0.1 | 0 | 0.2 | 0.2 | 0.4 | |
| Book value per share (Unadj.) | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.1 | |
| Adj. book value per share | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.4 | |
| Shares outstanding (eoy) | m | 126.20 | 126.20 | 126.20 | 126.20 | 126.35 | |
| Bonus/Rights/Conversions | - | - | - | - | ESOS | ||
| Price / Sales ratio | x | 3.0 | 3.3 | 2.3 | 2.1 | 2.7 | |
| Avg P/E ratio | x | 37.0 | 99.5 | 37.2 | 28.9 | 23.3 | |
| P/CF ratio (eoy) | x | 21.7 | 36.9 | 19.7 | 16.6 | 16.5 | |
| Price / Book Value ratio | x | 4.3 | 4.2 | 2.9 | 2.6 | 3.3 | |
| Dividend payout | % | 5.0 | 0 | 6.5 | 5.3 | 8.6 | |
| Avg Mkt Cap | Rs m | 94,057 | 95,723 | 72,300 | 69,120 | 103,108 | |
| No. of employees | `000 | 13.0 | 13.1 | 13.3 | 13.3 | 13.4 | |
| Total wages/salary | Rs m | 5,651 | 6,256 | 6,960 | 7,359 | 7,874 | |
| Avg. sales/employee | Rs Th | 2,416.4 | 2,213.3 | 2,414.6 | 2,477.4 | 2,807.0 | |
| Avg. wages/employee | Rs Th | 434.3 | 476.4 | 523.2 | 555.2 | 585.8 | |
| Avg. net profit/employee | Rs Th | 195.4 | 73.3 | 146.2 | 180.6 | 329.0 | |
| IPCA LABS INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 31,444 | 29,065 | 32,122 | 32,836 | 37,732 | |
| Other income | Rs m | 327 | 222 | 210 | 418 | 577 | |
| Total revenues | Rs m | 31,771 | 29,287 | 32,332 | 33,254 | 38,309 | |
| Gross profit | Rs m | 5,363 | 2,896 | 4,381 | 4,505 | 6,901 | |
| Depreciation | Rs m | 1,796 | 1,633 | 1,730 | 1,777 | 1,824 | |
| Interest | Rs m | 284 | 319 | 241 | 240 | 189 | |
| Profit before tax | Rs m | 3,611 | 1,166 | 2,621 | 2,905 | 5,465 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | -49 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 1,019 | 204 | 675 | 511 | 1,042 | |
| Profit after tax | Rs m | 2,542 | 962 | 1,945 | 2,394 | 4,422 | |
| Gross profit margin | % | 17.1 | 10.0 | 13.6 | 13.7 | 18.3 | |
| Effective tax rate | % | 28.2 | 17.5 | 25.8 | 17.6 | 19.1 | |
| Net profit margin | % | 8.1 | 3.3 | 6.1 | 7.3 | 11.7 | |
| IPCA LABS BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 19,348 | 16,219 | 17,418 | 19,455 | 23,778 | |
| Current liabilities | Rs m | 12,517 | 9,700 | 9,559 | 10,076 | 10,975 | |
| Net working cap to sales | % | 21.7 | 22.4 | 24.5 | 28.6 | 33.9 | |
| Current ratio | x | 1.5 | 1.7 | 1.8 | 1.9 | 2.2 | |
| Inventory Days | Days | 107 | 105 | 100 | 98 | 104 | |
| Debtors Days | Days | 73 | 56 | 57 | 67 | 66 | |
| Net fixed assets | Rs m | 20,540 | 21,429 | 20,779 | 20,435 | 20,368 | |
| Share capital | Rs m | 252 | 252 | 252 | 252 | 253 | |
| "Free" reserves | Rs m | 21,564 | 22,578 | 24,300 | 26,633 | 30,971 | |
| Net worth | Rs m | 21,965 | 22,592 | 24,553 | 26,886 | 31,224 | |
| Long term debt | Rs m | 4,987 | 4,843 | 3,517 | 2,340 | 1,409 | |
| Total assets | Rs m | 41,248 | 38,917 | 39,595 | 41,173 | 45,507 | |
| Interest coverage | x | 13.7 | 4.7 | 11.9 | 13.1 | 30.0 | |
| Debt to equity ratio | x | 0.2 | 0.2 | 0.1 | 0.1 | 0 | |
| Sales to assets ratio | x | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | |
| Return on assets | % | 6.9 | 3.3 | 5.5 | 6.4 | 10.1 | |
| Return on equity | % | 11.6 | 4.3 | 7.9 | 8.9 | 14.2 | |
| Return on capital | % | 14.3 | 5.4 | 10.2 | 10.8 | 17.3 | |
| Exports to sales | % | 52.9 | 49.2 | 48.6 | 47.6 | 45.9 | |
| Imports to sales | % | 16.7 | 15.3 | 14.2 | 14.9 | 16.6 | |
| Exports (fob) | Rs m | 16,624 | 14,299 | 15,617 | 15,642 | 17,308 | |
| Imports (cif) | Rs m | 5,247 | 4,445 | 4,571 | 4,884 | 6,266 | |
| Fx inflow | Rs m | 16,749 | 14,299 | 15,617 | 15,642 | 17,308 | |
| Fx outflow | Rs m | 6,956 | 5,822 | 4,571 | 4,884 | 6,266 | |
| Net fx | Rs m | 9,793 | 8,477 | 11,046 | 10,759 | 11,042 | |
| IPCA LABS CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 4,682 | 7,087 | 2,819 | 3,411 | 4,923 | |
| From Investments | Rs m | -6,893 | -2,183 | -1,488 | -1,354 | -1,563 | |
| From Financial Activity | Rs m | 2,505 | -4,615 | -1,591 | -1,304 | -1,832 | |
| Net Cashflow | Rs m | 294 | 288 | -260 | 753 | 1,528 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Premchand Godha (MD) | COMP SEC: Harish P. Kamath (VP - Legal) | YEAR OF INC: 1949 | BSE CODE: 524494 | FV (Rs): 2 | DIV YIELD (%): 0.2 |
More Pharmaceuticals Company Fact Sheets: PIRAMAL ENTERPRISES NOVARTIS FDC LTD. STRIDES PHARMA SCIENCE LUPIN
Compare IPCA LABS With: PIRAMAL ENTERPRISES NOVARTIS FDC LTD. STRIDES PHARMA SCIENCE LUPIN
Compare IPCA LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Buzz on the Street: A Look at Stocks, Sectors and the Economy(Podcast)
The stock markets in India remained rangebound this week. Economic data releases and third quarter results announcements were the focus of the week.
Views on news
IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)
Nov 12, 2019 | Updated on Nov 12, 2019For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Bet on These Smallcap Stocks for Success in 2020 (Profit Hunter)
Jan 14, 2020The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)
Jan 17, 2020Don't fall for the safe stocks narrative going around in the stock market these days.
More|
| |
OUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - ALEMBIC LTD COMPARISON
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.